A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine

Abstract

Cancer is a highly heterogeneous disease, and thus treatment responses vary greatly between patients. To improve therapy efficacy and outcome for cancer patients, more representative and patient-specific preclinical models are needed. Organoids and tumoroids are 3D cell culture models that typically retain the genetic and epigenetic characteristics, as well as the morphology, of their tissue of origin. Thus, they can be used to understand the underlying mechanisms of cancer initiation, progression, and metastasis in a more physiological setting. Additionally, co-culture methods of tumoroids and cancer-associated cells can help to understand the interplay between a tumor and its tumor microenvironment. In recent years, tumoroids have already helped to refine treatments and to identify new targets for cancer therapy. Advanced culturing systems such as chip-based fluidic devices and bioprinting methods in combination with tumoroids have been used for high-throughput applications for personalized medicine. Even though organoid and tumoroid models are complex in vitro systems, validation of results in vivo is still the common practice. Here, we describe how both animal- and human-derived tumoroids have helped to identify novel vulnerabilities for cancer treatment in recent years, and how they are currently used for precision medicine.

AggressiveKRASmutations direct TGF-β response towards partial EMT in patient-derived colorectal cancer tumoroids

“…Classical TGF-β studies utilized cell lines grown in 2D, which does not faithfully replicate several aspects important for EMT such as invasive properties, cell morphology and polarity, or cell-cell and cell-ECM interactions (34)(35)(36). The advent of innovative organoid and tumoroid models has provided suitable tools and novel insights into the effects of TGF-β on healthy and malignant cells (4,13,18,37,38).…”